

Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others) And Key Geographical Regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)): Industry Trends and Global Forecasts

<https://marketpublishers.com/r/AF54DB8D0934EN.html>

Date: July 2023

Pages: 716

Price: US\$ 4,799.00 (Single User License)

ID: AF54DB8D0934EN

Abstracts

The global antibody drug conjugate market is expected to reach USD 7.72 billion by 2023 and is anticipated to grow at a CAGR of 9.63% during the forecast period 2023-2035

Antibody drug conjugates (ADCs) are a class of engineered therapeutics that combine monoclonal antibodies with potent cytotoxic payloads through specialized chemical linkers. These innovations have propelled ADCs into the spotlight as potent treatments for a broad spectrum of conditions, including solid tumors and hematological malignancies. This is owing to advancements in antibody engineering, which facilitate site-specific conjugation and improve pharmacokinetic and pharmacodynamic characteristics. Presently, the USFDA has approved 14 antibody-drug conjugates for therapeutic application, such as ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), and others.

The notable success of ADC therapeutics can be attributed to their exceptional tumor selectivity and potent cell-killing abilities, while effectively limiting off-target toxicities. Ongoing advancements in this field are fueled by promising outcomes from previous clinical trials, particularly focusing on various solid tumor types. With continued innovation, strong financial backing from investors, and encouraging clinical trial results, the market for antibody drug conjugates is poised for significant expansion in the projected period.

Report Coverage

The report conducts an analysis of the antibody drug conjugates market, focusing on target disease indications, therapeutic areas, linkers, payloads, target antigens, and key geographical regions.

Examination of market growth factors—drivers, restraints, opportunities, and challenges—to understand their impact on the industry's development.

Evaluation of potential advantages and obstacles within the market, providing insights into the competitive landscape for leading market players.

Revenue forecasting for market segments across three major regions to gauge market potential and growth prospects.

Concise presentation of research insights to encapsulate the current status and future trajectory of the antibody drug conjugate market.

Introduction to antibody drug conjugates, encompassing their historical background, structural aspects, advantages, and pharmacokinetic properties.

Comprehensive assessment of the market landscape, analyzing nearly 400 antibody drug conjugates in terms of their developmental status, disease indications, therapeutic areas, treatment lines, dosing frequencies, therapy types, target antigens, antibody types, payloads, linkers, and developer information.

Insightful competitiveness analysis of biological targets using three-dimensional bubble representations and six-dimensional spider-web analysis, evaluating parameters such as development stages, therapy numbers, and indications.

Detailed profiles of leading antibody drug conjugate companies based on 2022 sales revenue, including company overviews, financial information (if available), product portfolios, recent developments, and future outlooks.

In-depth profiles of marketed ADC therapeutics, detailing their mechanisms of action, target antigens, linkers, payloads, therapy types, and sales data (if applicable).

Analysis of completed, ongoing, and planned clinical studies on ADCs, covering parameters like trial registration, phases, patient populations, sponsors, study designs, industry players, non-industry participants, and geographical regions.

Assessment of key opinion leaders (KOLs) involved in ADC-related clinical trials, considering KOL types, qualifications, affiliations, geographical locations, and prominent figures based on proprietary and third-party criteria.

Analysis of therapeutics in combination with ADCs across various indications and their potential evolution.

Detailed examination of partnerships formed in the ADC industry since 2014, focusing on partnership types, purposes, partner types, active players, and regional distributions.

Examination of funding and investments in the ADC domain since 2014, covering financing types, amounts invested, leading companies, investors, and geographical analyses.

In-depth analysis of ADC-related patents, including types, publication years, geographical locations, player types, assigned CPC symbols, organizations, and valuation assessments.

Study of grants awarded to research institutes engaged in ADC-related research since 2016, considering grant details, funding institutes, support periods, grant purposes, popular NIH departments, recipient organizations, and key regions.

Discussion on commercialization strategies pre, during, and post-launch of ADC products, featuring a framework outlining necessary steps and guidelines.

Analysis of promotional strategies employed by developers of marketed ADC products, examining approaches used for products like Adcetris, Besponsa, Enhertu, etc.

Success protocol analysis of recently approved ADC therapeutics based on parameters such as dosing frequency, efficacy, exclusivity, competition, prevalence, pricing, therapy type, and developer competition

Overview of conjugation and linker technologies utilized in ADC development.

Analysis of non-clinical data supporting First-In-Human (FIH) dose selection in ADCs, including findings from animal studies and methods for estimating FIH doses.

Discussion on factors influencing ADC pricing, presenting different pricing approaches for pharmaceutical companies in determining prices for their lead therapy candidates.

Case studies on ADC manufacturing challenges and contract service providers, alongside companion diagnostic companies offering tests for ADC treatment decisions.

Exploration of industry evolution through SWOT analysis, assessing trends,

drivers, challenges, and their relative impact on the overall industry landscape.

Key Market Companies

ADC Therapeutics

Astellas Pharma

AstraZeneca

Byondis

Daiichi Sankyo

Genentech

Gilead Sciences

ImmunoGen

Pfizer

RemeGen

Contents

1. PREFACE

- 1.1. Antibody Drug Conjugate Market Overview
- 1.2. Key Market Insights
- 1.3. Scope of the Report
- 1.4. Research Methodology
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Pillars of Cancer Therapy
- 3.3. Overview of Antibody Drug Conjugates
 - 3.3.1. History of Antibody Drug Conjugates
 - 3.3.2. Difference between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody Drug Conjugates
 - 3.3.3. Components of Antibody Drug Conjugates
 - 3.3.3.1. Antibody
 - 3.3.3.2. Cytotoxin
 - 3.3.3.3. Linker
 - 3.3.4. Advantages of Antibody Drug Conjugates Therapeutics over Traditional Therapeutics
 - 3.3.5. Pharmacokinetic Properties of Antibody-Drug Conjugates
 - 3.3.5.1. Absorption
 - 3.3.5.2. Distribution
 - 3.3.5.3. Metabolism and Elimination
- 3.4. Concluding Remarks

4. MARKET OVERVIEW

- 4.1. Chapter Overview
- 4.2. Antibody Drug Conjugates: Therapies Pipeline
 - 4.2.1. Analysis by Status of Development
 - 4.2.2. Analysis by Target Disease Indication

- 4.2.3. Analysis by Therapeutic Area
- 4.2.4. Analysis by Line of Treatment
- 4.2.5. Analysis by Dosing Frequency
- 4.2.6. Analysis by Type of Therapy
- 4.2.7. Analysis by Target Antigen
- 4.2.8. Analysis by Antibody Isotype
- 4.2.9. Analysis by Payload / Cytotoxin / Warhead
- 4.2.10. Analysis by Type of Payload
- 4.2.11. Analysis by Linker
- 4.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
- 4.3. Antibody Drug Conjugate: List of Therapy Developers
 - 4.3.1. Analysis by Year of Establishment
 - 4.3.2. Analysis by Company Size
 - 4.3.3. Analysis by Location of Headquarters
 - 4.3.4. Analysis by Company size and Location of Headquarters
 - 4.3.5. Most Active Players: Analysis by Number of Therapies

5. TARGET COMPETITIVENESS ANALYSIS

- 5.1. Chapter Overview
- 5.2. Key Parameters
- 5.3. Methodology
- 5.4. Target Competitiveness Analysis: Key Targets of Antibody Drug Conjugates
 - 5.4.1. Three-Dimensional Bubble Analysis
 - 5.4.1.1. Targets of Approved / Marketed Drugs
 - 5.4.1.2. Targets of Phase III Drugs
 - 5.4.1.3. Targets of Phase II Drugs
 - 5.4.1.4. Targets of Phase I Drugs
 - 5.4.1.5. Targets of Pre-Clinical Drugs
 - 5.4.2. Six-Dimensional Spider Web Analysis

6. COMPANY AND DRUG PROFILES

- 6.1. Chapter Overview
- 6.2. ADC Therapeutics
 - 6.2.1. Company Overview
 - 6.2.2. Financial Information
 - 6.2.3. Pipeline Overview
 - 6.2.3.1. Zynlonta

- 6.2.4. Recent Developments and Future Outlook
- 6.3. Astellas Pharma
 - 6.3.1. Company Overview
 - 6.3.2. Financial Information
 - 6.3.3. Pipeline Overview
 - 6.3.3.1. Padcev
 - 6.3.4. Recent Developments and Future Outlook
- 6.4. AstraZeneca
 - 6.4.1. Company Overview
 - 6.4.2. Financial Information
 - 6.4.3. Pipeline Overview
 - 6.4.3.1. Enhertu
 - 6.4.4. Recent Developments and Future Outlook
- 6.5. Byondis
 - 6.5.1. Company Overview
 - 6.5.2. Financial Information
 - 6.5.2.1. Pipeline Overview
 - 6.5.3. Trastuzumab duocarmazine
 - 6.5.4. Recent Developments and Future Outlook
- 6.6. Daiichi Sankyo
 - 6.6.1. Company Overview
 - 6.6.2. Financial Information
 - 6.6.3. Pipeline Overview
 - 6.6.3.1. Enhertu
 - 6.6.4. Recent Developments and Future Outlook
- 6.7. Genentech (Subsidiary of Roche)
 - 6.7.1. Company Overview
 - 6.7.2. Financial Information
 - 6.7.3. Pipeline Overview
 - 6.7.3.1. Kadcyla
 - 6.7.3.2. Polivy
 - 6.7.4. Recent Developments and Future Outlook
- 6.8. Gilead Sciences
 - 6.8.1. Company Overview
 - 6.8.2. Financial Information
 - 6.8.3. Pipeline Overview
 - 6.8.3.1. Trodelvy
 - 6.8.4. Recent Developments and Future Outlook
- 6.9. ImmunoGen

- 6.9.1. Company Overview
- 6.9.2. Financial Information
- 6.9.3. Pipeline Overview
 - 6.9.3.1. Elahere
- 6.9.4. Recent Developments and Future Outlook
- 6.10. Pfizer
 - 6.10.1. Company Overview
 - 6.10.2. Financial Information
 - 6.10.3. Pipeline Overview
 - 6.10.3.1. Mylotarg
 - 6.10.3.2. Besponsa
 - 6.10.4. Recent Developments and Future Outlook
- 6.11. RemeGen
 - 6.11.1. Company Overview
 - 6.11.2. Financial Information
 - 6.11.3. Pipeline Overview
 - 6.11.3.1. Disitamab vedotin
 - 6.11.4. Recent Developments and Future Outlook
- 6.12. Seagen
 - 6.12.1. Company Overview
 - 6.12.2. Financial Information
 - 6.12.3. Pipeline Overview
 - 6.12.3.1. Adcetris
 - 6.12.3.2. Padcev
 - 6.12.3.3. Tivdak
 - 6.12.4. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

- 7.1. Chapter Overview
- 7.2. Scope and Methodology
- 7.3. Antibody Drug Conjugates: Clinical Trial Analysis
 - 7.3.1. Analysis by Trial Registration Year
 - 7.3.2. Analysis by Trial Status
 - 7.3.3. Analysis by Trial Status and Patients Enrolled
 - 7.3.4. Analysis by Trial Registration Year and Trial Status
 - 7.3.5. Analysis by Trial Registration Year and Patients Enrolled
 - 7.3.6. Analysis by Trial Phase
 - 7.3.7. Analysis by Trial Phase and Patients Enrolled

- 7.3.8. Analysis by Type of Sponsor / Collaborator
- 7.3.9. Analysis by Target Population
- 7.3.10. Analysis by Study Design
- 7.3.11. Most Active Industry Players: Analysis by Number of Trials
- 7.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
- 7.3.13. Analysis of Clinical Trials by Geography
- 7.3.14. Analysis of Patients Enrolled by Geography

8. KEY OPINION LEADERS

- 8.1. Chapter Overview
- 8.2. Assumption and Key Parameters
- 8.3. Methodology
- 8.4. Antibody Drug Conjugates: Key Opinion Leaders
 - 8.4.1. Analysis by Type of KOLs
 - 8.4.2. Analysis by Qualification
 - 8.4.3. Analysis by Affiliated Organization
 - 8.4.4. Analysis by Type of Organization
 - 8.4.5. Analysis by Geographical Location of KOLs
 - 8.4.6. Most Prominent KOLs: Analysis by KOLs Activeness, Expertise and Strength
 - 8.4.7. Most Prominent KOLs: Analysis by RA score
 - 8.4.8. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9. COMBINATION THERAPIES

- 9.1. Chapter Overview
- 9.2. Combination Therapies: History of Development
- 9.3. Combination Therapies: FDA Guidelines
 - 9.3.1. Combination of Marketed Drugs
 - 9.3.2. Combinations of Marketed Drugs with New Molecular Entities
 - 9.3.3. Combination of New Molecular Entities
- 9.4. Combination Therapies: Antibody Drug Conjugates
 - 9.4.1. Completed / Ongoing Clinical Studies of Antibody Drug Conjugates
 - 9.4.1.1. Analysis by Type of Therapy
 - 9.4.2. Completed / Ongoing Clinical Studies of Antibody Drug Conjugate-based Combination Therapies
 - 9.4.2.1. Analysis by Phase of Development
 - 9.4.2.2. Analysis by Trial Status
 - 9.4.2.3. Analysis by Target Disease Indication

9.4.2.4. Most Popular Antibody Drug Conjugates Used in Combination Therapies: Analysis by Number of Trials

9.4.2.5. Most Popular Drug Class Used in Combination Therapies: Analysis by Number of Trials

9.4.2.6. Analysis by Target Disease Indication and Drug Class Used in Antibody Drug Conjugate-based Combination Therapies

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview

10.2. Partnership Models

10.3. Antibody Drug Conjugates: List of Partnerships and Collaborations

10.3.1. Analysis by Year of Partnership

10.3.2. Analysis by Type of Partnership

10.3.3. Analysis by Year and Type of Partnership

10.3.4. Analysis by Purpose of Partnership

10.3.5. Analysis by Type of Partner

10.3.6. Most Active Players: Analysis by Number of Partnerships

10.3.7. Analysis by Geography

10.3.7.1. International and Local Agreements

10.3.7.2. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS

11.1. Chapter Overview

11.2. Types of Funding

11.3. Antibody Drug Conjugates: List of Funding and Investment Analysis

11.3.1. Analysis by Year of Funding

11.3.2. Analysis by Amount Invested

11.3.3. Analysis by Type of Funding

11.3.4. Analysis by Year and Type of Funding

11.3.5. Analysis by Type of Investor

11.3.6. Analysis by Amount Invested by Geography

11.3.6.1. Analysis by Region

11.3.6.2. Analysis by Country

11.3.7. Most Active Players: Analysis by Number of Funding Instances

11.3.8. Most Active Players: Analysis by Amount Invested

11.3.9. Key Investors: Analysis by Number of Funding Instances

12. PATENT ANALYSIS

- 12.1. Chapter Overview
- 12.2. Scope and Methodology
- 12.3. Antibody Drug Conjugates: Patent Analysis
 - 12.3.1. Analysis by Patent Publication Year
 - 12.3.2. Analysis by Patent Application Year
 - 12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
 - 12.3.4. Analysis by Patent Jurisdiction
 - 12.3.5. Analysis by CPC Symbols
 - 12.3.6. Analysis by Type of Applicant
 - 12.3.7. Leading Industry Players: Analysis by Number of Patents
 - 12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
 - 12.3.9. Leading Individual Assignees: Analysis by Number of Patents
- 12.4. Antibody Drug Conjugate: Patent Benchmarking Analysis
 - 12.4.1. Analysis by Patent Characteristics
- 12.5. Antibody Drug Conjugate: Patent Valuation
- 12.6. Leading Patents by Number of Citations

13. ACADEMIC GRANTS ANALYSIS

- 13.1. Chapter Overview
- 13.2. Scope and Methodology
- 13.3. Antibody Drug Conjugates: Grants Analysis
 - 13.3.1. Analysis by Year of Grant Award
 - 13.3.2. Analysis by Amount Awarded
 - 13.3.3. Analysis by Funding Institute
 - 13.3.4. Analysis by Support Period
 - 13.3.5. Analysis by Type of Grant Application
 - 13.3.6. Analysis by Purpose of Grant Award
 - 13.3.7. Analysis by Activity Code
 - 13.3.8. Analysis by Study Section Involved
 - 13.3.9. Popular NIH Departments: Analysis by Number of Grants
 - 13.3.9.1. Prominent Program Officers: Analysis by Number of Grants
 - 13.3.9.2. Popular Recipient Organizations: Analysis by Number of Grants
 - 13.3.9.3. Popular Recipient Organizations: Analysis by Grant Amount
 - 13.3.10. Analysis by Region of Recipient Organization

14. KEY COMMERCIALIZATION STRATEGIES

- 14.1. Chapter Overview
- 14.2. Successful Drug Launch Strategy: ROOTS Framework
- 14.3. Successful Drug Launch Strategy: Product Differentiation
- 14.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development
- 14.5. Key Commercialization Strategies Adopted by the Companies Focused on Antibody Drug Conjugates
 - 14.5.1. Participation in the Global Events
 - 14.5.2. Collaboration with External Stakeholders and Pharmaceuticals Firms
 - 14.5.3. Geographical Expansion
 - 14.5.4. Awareness Through Product Website
- 14.6. Concluding Remarks

15. PROMOTIONAL ANALYSIS

- 15.1. Chapter Overview
- 15.2. Channels Used for Promotional Campaigns
- 15.3. Summary of Product Website
- 15.4. Summary of Patient Support Services and Informative Downloads
- 15.5. Adcetris: Promotional Analysis
 - 15.5.1. Drug Overview
 - 15.5.2. Product Website Analysis
 - 15.5.2.1. Message for Healthcare Professional
 - 15.5.2.2. Message for Patients
 - 15.5.2.3. Informative Downloads
 - 15.5.2.4. Patient Support Services
- 15.6. Besponsa: Promotional Analysis
 - 15.6.1. Drug Overview
 - 15.6.2. Product Website Analysis
 - 15.6.2.1. Message for Healthcare Professional
 - 15.6.2.2. Message for Patients
 - 15.6.2.3. Informative Downloads
 - 15.6.2.4. Patient Support Services
- 15.7. Enhertu: Promotional Analysis
 - 15.7.1. Drug Overview
 - 15.7.2. Product Website Analysis
 - 15.7.2.1. Message for Healthcare Professional
 - 15.7.2.2. Message for Patients

- 15.7.2.3. Informative Downloads
- 15.7.2.4. Patient Support Services
- 15.8. Kadcyła: Promotional Analysis
 - 15.8.1. Drug Overview
 - 15.8.2. Product Website Analysis
 - 15.8.2.1. Message for Healthcare Professional
 - 15.8.2.2. Message for patients
 - 15.8.2.3. Informative Downloads
 - 15.8.2.4. Patient Support Services
- 15.9. Mylotarg: Promotional Analysis
 - 15.9.1. Drug Overview
 - 15.9.2. Product Website Analysis
 - 15.9.2.1. Message for Healthcare Professional
 - 15.9.2.2. Message for patients
 - 15.9.2.3. Informative Downloads
 - 15.9.2.4. Patient Support Services
- 15.10. Polivy: Promotional Analysis
 - 15.10.1. Drug Overview
 - 15.10.2. Product Website Analysis
 - 15.10.2.1. Message for Healthcare Professional
 - 15.10.2.2. Message for Patients
 - 15.10.2.3. Informative Downloads
 - 15.10.2.4. Patient Support Services
- 15.11. Trodelvy: Promotional Analysis
 - 15.11.1. Drug Overview
 - 15.11.2. Product Website Analysis
 - 15.11.2.1. Message for Healthcare Professional
 - 15.11.2.2. Message for Patients
 - 15.11.2.3. Informative Downloads
 - 15.11.2.4. Patient Support Services

16. SUCCESS PROTOCOL ANALYSIS

- 16.1. Chapter Overview
- 16.2. Antibody Drug Conjugates: Success Protocol Analysis
- 16.3. Adcetris (Seagen / Takeda Oncology)
 - 16.3.1. Overview
 - 16.3.2. Approval Timeline
 - 16.3.3. Success Protocol Analysis

- 16.4. Aidixi (RemeGen)
 - 16.4.1. Overview
 - 16.4.2. Approval Timeline
 - 16.4.3. Success Protocol Analysis
- 16.5. Akalux (Rakuten Medical)
 - 16.5.1. Overview
 - 16.5.2. Approval Timeline
 - 16.5.3. Success Protocol Analysis
- 16.6. Besponsa (Pfizer / UCB)
 - 16.6.1. Overview
 - 16.6.2. Approval Timeline
 - 16.6.3. Success Protocol Analysis
- 16.7. Blenrep (GlaxoSmithKline)
 - 16.7.1. Overview
 - 16.7.2. Approval Timeline
 - 16.7.3. Success Protocol Analysis
- 16.8. Elahere (ImmunoGen)
 - 16.8.1. Overview
 - 16.8.2. Approval Timeline
 - 16.8.3. Success Protocol Analysis
- 16.9. Enhertu (Daiichi Sankyo / AstraZeneca)
 - 16.9.1. Overview
 - 16.9.2. Approval Timeline
 - 16.9.3. Success Protocol Analysis
- 16.10. Kadcyla (Genentech / ImmunoGen)
 - 16.10.1. Overview
 - 16.10.2. Approval Timeline
 - 16.10.3. Success Protocol Analysis
- 16.11. Padcev (Seagen / Astellas Pharma)
 - 16.11.1. Overview
 - 16.11.2. Approval Timeline
 - 16.11.3. Success Protocol Analysis
- 16.12. Polivy (Genentech)
 - 16.12.1. Overview
 - 16.12.2. Approval Timeline
 - 16.12.3. Success Protocol Analysis
- 16.13. Tivdak (Seagen / Genmab)
 - 16.13.1. Overview
 - 16.13.2. Approval Timeline

- 16.13.3. Success Protocol Analysis
- 16.14. Trodelvy (Gilead Sciences)
 - 16.14.1. Overview
 - 16.14.2. Approval Timeline
 - 16.14.3. Success Protocol Analysis
- 16.15. Zynlonta (ADC Therapeutics)
 - 16.15.1. Overview
 - 16.15.2. Approval Timeline
 - 16.15.3. Success Protocol Analysis
- 16.16. Concluding Remarks

17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS

- 17.1. Chapter Overview
- 17.2. Antibody Drug Conjugates: Conjugation Technologies
 - 17.2.1. Chemical Conjugation
 - 17.2.2. Enzymatic Conjugation
- 17.3. Antibody Drug Conjugates: List of Conjugation Technologies
- 17.4. Antibody Drug Conjugates: Linker Technologies
 - 17.4.1. Non-cleavable Linkers
 - 17.4.2. Cleavable Linker
- 17.5. Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
- 17.6. Concluding Remarks

18. ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING

- 18.1. Chapter Overview
- 18.2. Antibody Drug Conjugates: Non-Clinical Studies
- 18.3. ICH S9 Guidelines
- 18.4. Investigational New Drug (IND)-Enabling Study Designs
 - 18.4.1. Example Case: Kadcyla
- 18.5. Toxicities in Animal Models
- 18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
- 18.7. Other Key Considerations for Study Design

19. COST PRICE ANALYSIS

- 19.1. Chapter Overview
- 19.2. Factors Contributing Towards the High Price of Antibody-Drug Conjugates

19.3. Antibody Drug Conjugates Market: Cost Price Analysis

- 19.3.1. On the Basis of Associated Costs
- 19.3.2. On the Basis of Competition
- 19.3.3. On the Basis of Patient Segment

19.4. Reimbursement Considerations for Antibody-Drug Conjugates

20. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES

20.1. Chapter Overview

- 20.2. Key Steps in Antibody Drug Conjugate Manufacturing Process
- 20.3. Technical Challenges Related to Antibody Drug Conjugate Manufacturing
- 20.4. Challenges Associated with Supply Chain and Method Transfer
- 20.5. Limitations of In-House Manufacturing
- 20.6. Investments in Antibody Drug Conjugate Manufacturing Capability Expansions
- 20.7. Collaborations Established for Antibody-Drug Conjugate Manufacturing
- 20.8. Growing Demand for Antibody-Drug Conjugate Contract Manufacturing
- 20.9. CMOs with Linker Manufacturing Capabilities
- 20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
- 20.11. CMOs with Conjugation Capabilities
- 20.12. Antibody Drug Conjugate One-Stop-Shops
- 20.13. Increasing Demand for One-Stop-Shops

21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS

21.1. Chapter Overview

- 21.1.1. Advantages of Companion Diagnostics
- 21.1.2. Challenges Associated with the Development of Companion Diagnostics
- 21.2. Companion Diagnostics for Antibody Drug Conjugates
- 21.3. Companion Diagnostics For Antibody Therapeutics
 - 21.3.1. Analysis by Target Antigen
 - 21.3.2. Analysis by Type of Cancer
- 21.4. Most Prominent Players: Analysis by Number of Tests

22. SWOT ANALYSIS

- 22.1. Chapter Overview
- 22.2. Strengths

- 22.2.1. Improved Safety and Patient Adherence
- 22.2.2. Rise of Next-Generation Conjugation Technologies
- 22.2.3. Robust Pipeline with Multiple Late Stage Product Candidates
- 22.2.4. Growing Involvement of Academic Institutes
- 22.3. Weaknesses
 - 22.3.1. Technical Complexities Associated with Product Development
 - 22.3.2. Manufacturing, Logistics and Supply Chain Challenges
 - 22.3.3. Batch to Batch Inconsistencies
- 22.4. Opportunities
 - 22.4.1. Increasing Collaborations and VC Funding
 - 22.4.2. Widening Therapeutics Reach
 - 22.4.3. Life Cycle Management
 - 22.4.4. Combination Therapies
 - 22.4.5. Opportunities for CMOs
- 22.5. Threats
 - 22.5.1. Failure of Clinical / Marketed Candidates
 - 22.5.2. Increased Competition from Other Therapeutic Classes

23. MARKET FORECAST AND OPPORTUNITY ANALYSIS

- 23.1. Chapter Overview
- 23.2. Forecast Methodology and Key Assumptions
- 23.3. Global Antibody Drug Conjugates Market, 2023-2035
 - 23.3.1. Global Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
 - 23.3.1.1. Antibody Drug Conjugates Market for Breast Cancer, 2023-2035
 - 23.3.1.2. Antibody Drug Conjugates Market for B-cell Lymphoma, 2023-2035
 - 23.3.1.3. Antibody Drug Conjugates Market for Lung Cancer, 2023-2035
 - 23.3.1.4. Antibody Drug Conjugates Market for Multiple Myeloma, 2023-2035
 - 23.3.1.5. Antibody Drug Conjugates Market for Renal Cancer, 2023-2035
 - 23.3.1.6. Antibody Drug Conjugates Market for Gastric Cancer, 2023-2035
 - 23.3.1.7. Antibody Drug Conjugates Market for Cervical Cancer, 2023-2035
 - 23.3.1.8. Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, 2023-2035
 - 23.3.1.9. Antibody Drug Conjugates Market for Other Disease Indications, 2023-2035
 - 23.3.2. Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035
 - 23.3.2.1. Antibody Drug Conjugates Market for Solid Tumors, 2023-2035
 - 23.3.2.2. Antibody Drug Conjugates Market for Hematological Cancer, 2023-2035

23.3.3. Global Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035

23.3.3.1. Antibody Drug Conjugates Market for Valine-Citrulline Linker, 2023-2035

23.3.3.2. Antibody Drug Conjugates Market for Tetrapeptide-Based Linker, 2023-2035

23.3.3.3. Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, 2023-2035

23.3.3.4. Antibody Drug Conjugates Market for Maleimide Linker, 2023-2035

23.3.3.5. Antibody Drug Conjugates Market for Maleimidocaproyl Linker, 2023-2035

23.3.3.6. Antibody Drug Conjugates Market for Valine-Alanine Linker, 2023-2035

23.3.3.7. Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, 2023-2035

23.3.3.8. Antibody Drug Conjugates Market for Other Linkers, 2023-2035

23.3.4. Antibody Drug Conjugates Market: Distribution by Type of Payload, 2023 and 2035

23.3.4.1. Antibody Drug Conjugates Market for Monomethyl Auristatin E Payloads, 2023-2035

23.3.4.2. Antibody Drug Conjugates Market for DM1 Payloads, 2023-2035

23.3.4.3. Antibody Drug Conjugates Market for SN-38 / Irinotecan Payloads, 2023-2035

23.3.4.4. Antibody Drug Conjugates Market for Monomethyl Auristatin F Payloads, 2023-2035

23.3.4.5. Antibody Drug Conjugates Market for Duocarmycin Payloads, 2023-2035

23.3.4.6. Antibody Drug Conjugates Market for SG3199 Payloads, 2023-2035

23.3.4.7. Antibody Drug Conjugates Market for Ozogamicin Payloads, 2023-2035

23.3.4.8. Antibody Drug Conjugates Market for DM4 Payloads, 2023-2035

23.3.4.9. Antibody Drug Conjugates Market for Other Payloads, 2023-2035

23.3.5. Global Antibody Drug Conjugates Market: Distribution by Target Antigen, 2023 and 2035

23.3.5.1. Antibody Drug Conjugates Market for HER-2 (ERBB2), 2023-2035

23.3.5.2. Antibody Drug Conjugates Market for CD79b, 2023-2035

23.3.5.3. Antibody Drug Conjugates Market for TROP-2, 2023-2035

23.3.5.4. Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), 2023-2035

23.3.5.5. Antibody Drug Conjugates Market for CD19, 2023-2035

23.3.5.6. Antibody Drug Conjugates Market for Nectin 4, 2023-2035

23.3.5.7. Antibody Drug Conjugates Market for Tissue Factor, 2023-2035

23.3.5.8. Antibody Drug Conjugates Market for CD22, 2023-2035

23.3.5.9. Antibody Drug Conjugates Market for CD30, 2023-2035

- 23.3.5.10. Antibody Drug Conjugates Market for CEACAM5, 2023-2035
- 23.3.5.11. Antibody Drug Conjugates Market for Other Target Antigens, 2023-2035
- 23.3.6. Antibody Drug Conjugates Market: Distribution by Geographical Regions, 2023 and 2035
 - 23.3.6.1. Antibody Drug Conjugates Market in North America, 2023-2035
 - 23.3.6.1.1. Antibody Drug Conjugates Market in US, 2023-2035
 - 23.3.6.1.2. Antibody Drug Conjugates Market in Canada, 2023-2035
 - 23.3.6.2. Antibody Drug Conjugates Market in Europe, 2023-2035
 - 23.3.6.2.1. Antibody Drug Conjugates Market in Germany, 2023-2035
 - 23.3.6.2.2. Antibody Drug Conjugates Market in UK, 2023-2035
 - 23.3.6.2.3. Antibody Drug Conjugates Market in France, 2023-2035
 - 23.3.6.2.4. Antibody Drug Conjugates Market in Italy, 2023-2035
 - 23.3.6.2.5. Antibody Drug Conjugates Market in Spain, 2023-2035
 - 23.3.6.3. Antibody Drug Conjugates Market in Asia-Pacific, 2023-2035
 - 23.3.6.3.1. Antibody Drug Conjugates Market in China, 2023-2035
 - 23.3.6.3.2. Antibody Drug Conjugates Market in Australia, 2023-2035
 - 23.3.6.3.3. Antibody Drug Conjugates Market in Japan, 2023-2035
- 23.4. Antibody Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
 - 23.4.1. Adcetris
 - 23.4.1.1. Sales Forecast (USD Billion)
 - 23.4.1.2. Net Present Value (USD Billion)
 - 23.4.1.3. Value Creation Analysis
 - 23.4.2. Aidixi
 - 23.4.2.1. Sales Forecast (USD Billion)
 - 23.4.2.2. Net Present Value (USD Billion)
 - 23.4.2.3. Value Creation Analysis
 - 23.4.3. Besponsa
 - 23.4.3.1. Sales Forecast (USD Billion)
 - 23.4.3.2. Net Present Value (USD Billion)
 - 23.4.3.3. Value Creation Analysis
 - 23.4.4. Blenrep
 - 23.4.4.1. Sales Forecast (USD Billion)
 - 23.4.4.2. Net Present Value (USD Billion)
 - 23.4.4.3. Value Creation Analysis
 - 23.4.5. Elahere
 - 23.4.5.1. Sales Forecast (USD Billion)
 - 23.4.5.2. Net Present Value (USD Billion)
 - 23.4.5.3. Value Creation Analysis
 - 23.4.6. Enhertu

- 23.4.6.1. Sales Forecast (USD Billion)
- 23.4.6.2. Net Present Value (USD Billion)
- 23.4.6.3. Value Creation Analysis
- 23.4.7. Kadcyła
 - 23.4.7.1. Sales Forecast (USD Billion)
 - 23.4.7.2. Net Present Value (USD Billion)
 - 23.4.7.3. Value Creation Analysis
- 23.4.8. Padcev
 - 23.4.8.1. Sales Forecast (USD Billion)
 - 23.4.8.2. Net Present Value (USD Billion)
 - 23.4.8.3. Value Creation Analysis
- 23.4.9. Polivy
 - 23.4.9.1. Sales Forecast (USD Billion)
 - 23.4.9.2. Net Present Value (USD Billion)
 - 23.4.9.3. Value Creation Analysis
- 23.4.10. Tivdak
 - 23.4.10.1. Sales Forecast (USD Billion)
 - 23.4.10.2. Net Present Value (USD Billion)
 - 23.4.10.3. Value Creation Analysis
- 23.4.11. Trodelvy
 - 23.4.11.1. Sales Forecast (USD Billion)
 - 23.4.11.2. Net Present Value (USD Billion)
 - 23.4.11.3. Value Creation Analysis
- 23.4.12. Zynlonta
 - 23.4.12.1. Sales Forecast (USD Billion)
 - 23.4.12.2. Net Present Value (USD Billion)
 - 23.4.12.3. Value Creation Analysis
- 23.4.13. Datopotamab Deruxtecan
 - 23.4.13.1. Sales Forecast (USD Billion)
 - 23.4.13.2. Net Present Value (USD Billion)
 - 23.4.13.3. Value Creation Analysis
- 23.4.14. Patritumab Deruxtecan
 - 23.4.14.1. Sales Forecast (USD Billion)
 - 23.4.14.2. Net Present Value (USD Billion)
 - 23.4.14.3. Value Creation Analysis
- 23.4.15. SHR-A1811
 - 23.4.15.1. Sales Forecast (USD Billion)
 - 23.4.15.2. Net Present Value (USD Billion)
 - 23.4.15.3. Value Creation Analysis

23.4.16. SKB264

- 23.4.16.1. Sales Forecast (USD Billion)
- 23.4.16.2. Net Present Value (USD Billion)
- 23.4.16.3. Value Creation Analysis

23.4.17. TAA013

- 23.4.17.1. Sales Forecast (USD Billion)
- 23.4.17.2. Net Present Value (USD Billion)
- 23.4.17.3. Value Creation Analysis

23.4.18. Telisotuzumab Vedotin

- 23.4.18.1. Sales Forecast (USD Billion)
- 23.4.18.2. Net Present Value (USD Billion)
- 23.4.18.3. Value Creation Analysis

23.4.19. Trastuzumab Duocarmazine

- 23.4.19.1. Sales Forecast (USD Billion)
- 23.4.19.2. Net Present Value (USD Billion)
- 23.4.19.3. Value Creation Analysis

23.4.20. Tusamitamab Ravtansine

- 23.4.20.1. Sales Forecast (USD Billion)
- 23.4.20.2. Net Present Value (USD Billion)
- 23.4.20.3. Value Creation Analysis

23.4.21. Upifitamab Rilsodotin

- 23.4.21.1. Sales Forecast (USD Billion)
- 23.4.21.2. Net Present Value (USD Billion)
- 23.4.21.3. Value Creation Analysis

24. EXECUTIVE INSIGHTS

24.1. Chapter Overview

24.2. Oxford Biotherapeutics

- 24.2.1. Company Snapshot
- 24.2.2. Interview Transcript: Christian Rohlf, Founder and Chief Executive Officer

24.3. Angiex

- 24.3.1. Company Snapshot
- 24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Operating Officer

24.4. Syndivia

- 24.4.1. Company Snapshot
- 24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer

24.5. BSP Pharmaceuticals

- 24.5.1. Company Snapshot

- 24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
- 24.6. PolyTherics (an Abzena company)
 - 24.6.1. Company Snapshot
 - 24.6.2. Interview Transcript: John Burt, Former Chief Executive Officer
- 24.7. CureMeta
 - 24.7.1. Company Snapshot
 - 24.7.2. Interview Transcript: Michael Schopperle, Founder and Chief Executive Officer
- 24.8. CytomX Therapeutics
 - 24.8.1. Company Snapshot
 - 24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy
- 24.9. NBE-Therapeutics
 - 24.9.1. Company Snapshot
 - 24.9.2. Interview Transcript: Wouter Verhoeven, Former Chief Business Officer
- 24.10. Cerbios-Pharma
 - 24.10.1. Company Snapshot
 - 24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
- 24.11. Eisai
 - 24.11.1. Company Snapshot
 - 24.11.2. Interview Transcript: Toshimitsu Uenaka, President and Takashi Owa, Senior Vice President and Chief Scientific Officer
- 24.12. AbTis
 - 24.12.1. Company Snapshot
 - 24.12.2. Interview Transcript: Justin Oh, Chief Business Officer
- 24.13. AmbrX
 - 24.13.1. Company Snapshot
 - 24.13.2. Interview Transcript: Sukumar Sakamuri, Former Vice President and Head of Chemistry
- 24.14. Synaffix
 - 24.14.1. Company Snapshot
 - 24.14.2. Interview Transcript: Anthony DeBoer, Vice President, Business Development
- 24.15. Pierre Fabre
 - 24.15.1. Company Snapshot
 - 24.15.2. Interview Transcript: Christian Bailly, Former Director
- 24.16. Catalent Pharma Solutions
 - 24.16.1. Company Snapshot
 - 24.16.2. Interview Transcript: Jennifer L. Mitcham, Former Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Former Group Product Manager
- 24.17. Lonza

- 24.17.1. Company Snapshot
- 24.17.2. Interview Transcript: Laurent Ducry, Former Head of Bioconjugates
Commercial Development
- 24.18. Piramal Healthcare
 - 24.18.1. Company Snapshot
 - 24.18.2. Interview Transcript: Mark Wright, Former Site Head
- 24.19. Ajinomoto Bio-Pharma Services
 - 24.19.1. Company Snapshot
 - 24.19.2. Interview Transcript: Tatsuya Okuzumi, General Manager, Business
Development, CDMO Business
- 24.20. Cardiff University
 - 24.20.1. Company Snapshot
 - 24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
- 24.21. Anonymous, Director, Business Development, Leading CMO
- 24.22. Anonymous, Chief Executive Officer, Leading CMO

25. CONCLUSION

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others) And Key Geographical Regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)): Industry Trends and Global Forecasts

Product link: <https://marketpublishers.com/r/AF54DB8D0934EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF54DB8D0934EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970